Home > Healthcare > Pharmaceuticals > Vaccines > Hepatitis B Vaccine Market

Hepatitis B Vaccine Market Analysis

Report ID: GMI5826
Published Date: May 2023
Report Format: PDF

Download Free Sample

Hepatitis B Vaccine Market Analysis

Global Hepatitis B Vaccine Market Size, By Type,

By type, the hepatitis B vaccine market is classified into single antigen vaccine and combination vaccine. The combination vaccine segment accounted over 65% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Hepatitis B combination vaccines are formulated to provide protection against multiple diseases in a single shot, reducing the number of injections required for immunization. Also, combination hepatitis B vaccine is the combination of hepatitis B vaccine with other relevant antigens, such as those for diphtheria, tetanus, pertussis, other infections. These vaccines offer convenience, increased compliance, and improved vaccination coverage rates.

Global Hepatitis B Vaccine Market Revenue Share, By End-use

Learn more about the key segments shaping this market

Download Free Sample

Based on end-use, the hepatitis B vaccine market is segmented into hospitals, clinics and others. The hospitals are projected to register USD 3.6 billion in 2032. This is owing to the primary vaccination dose administration to new-borns infants before the discharge from the hospitals as new-born infants are at a high risk of acquiring hepatitis B infection. Also, hospitals offer accessibility and convenience for individuals seeking hepatitis B vaccination during their regular visits for healthcare needs. Furthermore, developed infrastructure and well-established storage facilities contributes to streamlined operations and reduces the risk of vaccine shortage and wastage in the hospital.

Looking for region specific data?

Download Free Sample

North America hepatitis B vaccine market accounted for over 40.6% business share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. Increasing prevalence of hepatitis B infections coupled with the increasing population at risk, including newborns, healthcare workers among others is expected to fuel the market growth in the region. Also, growing awareness pertaining to the importance of immunization and preventive healthcare practices is projected to fuel the market demand.

Increasing investments in R&D to enhance vaccine efficacy will reduce the number of doses required, hereby significantly proliferate the market growth. Furthermore, rising government initiatives for promoting education and vaccination campaigns to enhance vaccine coverage rates will significantly drive the value in the North America region.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for hepatitis B vaccine generated USD 3.3 billion in 2022 and is estimated to grow at 5.1% CAGR and amass USD 5.7 billion by 2032 driven by the high prevalence of chronic infection, liver cirrhosis, and liver cancer.

The combination vaccine segment accounted for over 65% market share in 2022 and is projected to witness robust growth over 2023-2032 owing to their increasing use to provide protection against multiple diseases in a single shot.

The North America hepatitis B vaccine industry held over 40.6% revenue share in 2022 and is set to grow at a considerable rate through 2032 attributed to the high prevalence of hepatitis B infections, coupled with the increasing population at risk, including newborns and healthcare workers.

The top firms operating in the hepatitis B vaccine industry are Merck & Co., Inc, Sanofi S.A., GlaxoSmithKline plc., and Dynavax Technologies Corporation, among others.